# Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

> **NCT01924533** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 525 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01924533
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-03
- **Primary completion:** 2016-04-04
- **Final completion:** 2023-03-27
- **Target enrollment:** 525 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01924533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01924533, "Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01924533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*